Home > Knowledge > Content

Product Categories

Contact Information

  • Shanghai LianLu Industrial Co., Ltd
  • Tel: +86-21-57935561
  • Fax: +86-21-57937068
  • Add: Room 702, Building 46, No.900, Haili Rd, Jinshan, Shanghai 201508, China
  • Email: lianluxs007@shllgf.com
  • Problems facing pharmaceutical intermediates
    Nov 08, 2018

    Pharmaceutical intermediates are an important part of fine chemicals, and their development level is a sign of a country's chemical modernization level. Over the years, the pharmaceutical intermediate industry has been the focus of intense investment and fierce competition in countries around the world. In the past two decades, the pharmaceutical industry in the world has made unprecedented progress. By the end of the 1990s, the world pharmaceutical market had reached 256 billion US dollars / a, and pesticide sales reached 23 billion US dollars / a. As far as medicine is concerned, although biotechnology and genetic drugs have been developing as a newcomer in the past decade, important medicines are constantly being accepted. In the future, the development trend of the world pharmaceutical industry is: high technology, high requirements, high speed, and high concentration.

    The main features are the following:

    1. New drugs emerge in an endless stream and variety updates are accelerated. For example, quinolone acid antibacterial agents have synthesized more than 20,000 compounds and carried out antibacterial screening in the past 30 years. Among the studies developed between 1962 and 1969 were Nalidixic acid, Oxalinic acid and Piromidic acid. It was replaced by Flumequine and Pipemidic acid between 1970 and 1977. Fluoroquinolone acids have appeared since 1978 and become the third generation of quinolone antibacterials, such as propofolfloxacin (ciprofloxacin), lomefloxacin (Lomefloxacin, Lomefloxacin, Ny-198) and Ofloxacin (fluoxin, Ofloxacin) and the like. They have a broad spectrum of antibacterial activity and are more active, comparable in efficacy to third or fourth generation cephalosporins.

    2, the difficulty of creating new drugs is getting bigger and bigger, the management department's requirements for the efficacy and safety of drugs are getting higher and higher, and the investment in research and development has increased dramatically. At the same time, research and development of new drugs is long-term and continuous; and there is great risk. To adapt to competition in high-tech fields, it will cost a lot of money. In economically developed countries, research and development expenses as a percentage of turnover (C/A≈6.3%, C/B≈17.7%) exceeded the turnover margin (D/A≈5.2%). A-total turnover, B-pharmaceutical turnover, C-research and development fee, D-total profit.

    3. As a high-tech industry, the pharmaceutical industry needs high knowledge content. Pharmaceutical industry companies in various countries are constantly strengthening the strength of their research teams. For example, researchers in the US pharmaceutical industry account for 15% of the employees, of which 26.7% are doctors and masters.